Advertisement
UK markets closed

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • CRUDE OIL

    83.36
    +1.46 (+1.78%)
     

  • GOLD FUTURES

    2,335.70
    -10.70 (-0.46%)
     

  • DOW

    38,507.63
    +267.65 (+0.70%)
     

  • Bitcoin GBP

    53,415.77
    +49.71 (+0.09%)
     

  • CMC Crypto 200

    1,431.23
    +16.47 (+1.16%)
     

  • NASDAQ Composite

    15,698.75
    +247.45 (+1.60%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

SomaLogic to Announce First Quarter 2022 Financial Results

SomaLogic, Inc.
·1-min read
SomaLogic, Inc.
SomaLogic, Inc.

BOULDER, Colo., April 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (844) 535-4027 for domestic callers or (270) 215-9487 for international callers, using conference ID: 3567018. A live audio webcast and an archive of the presentation will be available through the Investors page of SomaLogic’s corporate website at https://investors.somalogic.com/.

About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

ADVERTISEMENT

The SomaScan Platform is for Research Use Only (RUO) and has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic or patient management purposes.

SomaLogic Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com

Investor Contact
Marissa Bych or Lynn Lewis
Gilmartin Group LLC
investors@somalogic.com